Advocacy intelligence hub — real-time data for patient organizations
Livtencity: FDA approved
Treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet
CytoGam: FDA approved
#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease associated transplantation of kidney (all other), lung, liver, pancreas and heart.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
CytoGam
CSL Behring LLC
Patient Assistance Programs1
Livtencity
Takeda Pharmaceuticals U.S.A., Inc.
Livtencity
(maribavir)Orphan drugTakeda Pharmaceuticals U.S.A., Inc.
Cytomegalovirus pUL97 Kinase Inhibitor [EPC]
12.1 Mechanism of Action LIVTENCITY is an antiviral drug against human CMV [see Microbiology (12.4) ] .
CytoGam
(Cytomegalovirus immune globulin (human))Orphan drugCSL Behring LLC
Browse all Severe disseminated cytomegalovirus infection in immunocompetent patients news →
View all Severe disseminated cytomegalovirus infection in immunocompetent patients specialists →